Literature DB >> 16908353

T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.

Cynthia M Magro1, Carl D Morrison, Nyla Heerema, Pierluigi Porcu, Novie Sroa, April C Deng.   

Abstract

BACKGROUND: T-cell prolymphocytic leukemia (T-PLL), formerly categorized as T-cell chronic lymphocytic leukemia, is a rare and aggressive hematologic malignancy. Although the skin is characteristically involved, it is not a well-recognized entity in the dermatologic literature.
METHODS: Six cases of cutaneous T-PLL are presented from a clinical, light microscopic, and phenotypic perspective.
RESULTS: The patient population comprised 2 women and 4 men, with a mean age of 69.8 years. The disease was associated in all with skin involvement with facial preference; edema, purpura, and lesional symmetry were characteristic. The skin biopsies demonstrated a largely non-epidermotropic angiocentric lymphocytic infiltrate with accompanying hemorrhage. The cells showed irregular- to reniform-shaped nuclei with small nucleoli and eosinophilic rims of cytoplasm. Phenotypic studies revealed three prevailing profiles: CD4 dominant in 4, CD8 dominant in one, and co-expression of CD4 and CD8 in one. CD3 loss was seen in one case. All expressed T-cell leukemia 1 (TCL-1) and CD7; cutaneous lymphocyte antigen expression was discernible in a dot-like perinuclear array. All cases tested excluding one expressed TCL-1 and CD52. In two cases tested, T-cell receptor beta rearrangements were observed. Cytogenetic studies demonstrated a paracentromeric chromosome 14 inversion. Polysomy 8 and MYC amplification was seen in one case, manifesting an aggressive clinical course. Four patients died from their disease within 18 months of diagnosis. LIMITATIONS: Cytogenetic MYC amplification, FISH, and TCR beta studies were conducted on each of 2 cases, respectively, due to limitations of tissue block samples and/or peripheral blood. cMYC translocation studies were conducted on 3 of the 6 cases, again due to limitations imposed by the tissue samples on the cases. The last case was recently diagnosed and, therefore, long-term follow-up is not possible.
CONCLUSION: T-PLL is a distinctive post-thymic T-cell malignancy with frequent cutaneous tropism. A diagnosis is possible in almost all cases based on characteristic clinical, light microscopic, phenotypic, and cytogenetic features. While a chromosome 14 inversion is highly characteristic, additional inherent cytogenetic differences, such as trisomy 8 with CMYC over-amplification, may account for some case to case variation in clinical course.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908353     DOI: 10.1016/j.jaad.2006.04.060

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  A case of T cell prolymphocytic leukemia involving blast transformation.

Authors:  Kunimoto Ichikawa; Masaaki Noguchi; Hidenori Imai; Yasunobu Sekiguchi; Mutsumi Wakabayashi; Tomohiro Sawada; Norio Komatsu
Journal:  Int J Hematol       Date:  2011-04-21       Impact factor: 2.490

2.  Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration.

Authors:  Buthaina Al-Musalhi; Nancy Shehata; Robin Billick
Journal:  Oman Med J       Date:  2016-01

3.  T-cell prolymphocytic leukemia presenting with erythematous patches, plaques, and erythema gyratum-like lesions masquerading as Sézary syndrome.

Authors:  Leah Cohen; Adel Haque; Sophia Ma; Ling Zhang; Lubomir Sokol; Lucia Seminario-Vidal
Journal:  JAAD Case Rep       Date:  2019-08-05

Review 4.  Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.

Authors:  Indumathy Varadarajan; Karen Ballen
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

5.  A case of leukaemia cutis in a dog with T-cell chronic lymphocytic leukaemia.

Authors:  Hyeona Bae; Ji-Seon Yoon; Eulsoo Choi; Sang-Hyun Kim; Dong-In Jung; Jinho Park; Sang-Ki Kim; Dae Young Kim; DoHyeon Yu
Journal:  Vet Med Sci       Date:  2022-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.